Price$3.42-0.01 (-0.29%)
01:30 PM07:45 PM
News · 26 weeks36-33%
2025-12-072026-05-31
Mix1890d
- Other8(44%)
- SEC Filings4(22%)
- Earnings3(17%)
- Dividends1(6%)
- Analyst1(6%)
- Insider1(6%)
Latest news
25 items- INSIDERVP, Chief Accounting Officer Roth Anthony M. was granted 30,000 shares, increasing direct ownership by 61% to 78,833 units (SEC Form 4)4 - Embecta Corp. (0001872789) (Issuer)
- PRembecta to Participate in Investor EventsPARSIPPANY, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today announced that management will participate in the following investor events: 2026 Jefferies Global Healthcare Conference Management will host one-on-one investor meetings on Wednesday, June 3, 2026, at the Marriott Marquis, New York City. TD Cowen Diabetes Tech Summit Management will host a fireside session on Friday, June 5, 2026, at 9:40 a.m. CT / 10:40 a.m. ET, at the Westin New Orleans, LA. 2026 Goldman Sachs 47th Annual Global Healthcare Conference Managemen
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Embecta Corp.SCHEDULE 13G/A - Embecta Corp. (0001872789) (Subject)
- SECSEC Form SD filed by Embecta Corp.SD - Embecta Corp. (0001872789) (Filer)
- SECEmbecta Corp. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Embecta Corp. (0001872789) (Filer)
- PRembecta Completes Acquisition of Owen Mumford Holdings LimitedPARSIPPANY, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global leader in diabetes care technology, today announced that it has completed its previously announced transaction to acquire Owen Mumford Holdings Limited ("Owen Mumford"), a privately held, UK-based innovator and manufacturer of medical devices and drug delivery technologies. On March 19, 2026, the two companies announced a definitive agreement for embecta to acquire Owen Mumford for an upfront cash payment of £100 million and up to an additional £50 million in performance-based payments based on net sales of the Aidaptus® next generation auto-injector platform in the three-year period follo
- PRembecta to Participate at the 2026 BofA Securities Global Health Care ConferencePARSIPPANY, N.J., May 08, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (embecta) (NASDAQ:EMBC) today announced that management will present at the 2026 BofA Securities Global Health Care Conference in Las Vegas on Wednesday, May 13, 2026 at 3:00 p.m. PT / 6:00 p.m. ET. Audio webcasts of the presentations will be accessible under the "News & Events" section of the Company's investor relations website at investors.embecta.com. About embecta embecta is a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, helping to improve lives through innovative solutions, partnerships, and the passion of approximately 2,000 employees aroun
- ANALYSTEmbecta Corp. downgraded by BTIG ResearchBTIG Research downgraded Embecta Corp. from Buy to Neutral
- SECSEC Form SCHEDULE 13G filed by Embecta Corp.SCHEDULE 13G - Embecta Corp. (0001872789) (Subject)
- SECSEC Form 10-Q filed by Embecta Corp.10-Q - Embecta Corp. (0001872789) (Filer)
- SECEmbecta Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Embecta Corp. (0001872789) (Filer)
- PREmbecta Corp. Reports Second Quarter Fiscal 2026 Financial ResultsPARSIPPANY, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today reported second quarter fiscal 2026 financial results. Visit the company's Investor Relations website at http://investors.embecta.com to view the detailed second quarter fiscal 2026 earnings press release and investor presentation. The company will host a conference call and live audio webcast for analysts and investors at 8:00 a.m. ET today, May 5, 2026, which is accessible here, or access the teleconference here. The live webcast can also be accessed via the company'
- PRembecta Announces Quarterly Cash DividendPARSIPPANY, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. ("embecta") (NASDAQ:EMBC) has declared a quarterly cash dividend of $0.01 for each issued and outstanding share of the Company's common stock. The dividend is payable on June 15, 2026 to stockholders of record at the close of business on May 28, 2026.About embecta embecta is a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, helping to improve lives through innovative solutions, partnerships, and the passion of approximately 2,000 employees around the globe. For more information, visit embecta.com or follow our social channel
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Embecta Corp.SCHEDULE 13G/A - Embecta Corp. (0001872789) (Subject)
- PRembecta to Report Fiscal Second Quarter Financial ResultsPARSIPPANY, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, will host a conference call to discuss its fiscal second quarter 2026 financial results, provide an operational update, and host a question and answer session, at 8:00 a.m. Eastern Time (ET) on Tuesday, May 5, 2026. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company's website at investors.embecta.com. A webcast replay of the call will be available beginning at 11:00
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Embecta Corp.SCHEDULE 13G/A - Embecta Corp. (0001872789) (Subject)
- SECEmbecta Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Embecta Corp. (0001872789) (Filer)
- PRembecta Announces Definitive Agreement to Acquire Owen Mumford Holdings LimitedPARSIPPANY, N.J., March 19, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. ("Embecta") (NASDAQ:EMBC), a global leader in diabetes care technology, today announced that it has entered into a definitive agreement to acquire Owen Mumford Holdings Limited ("Owen Mumford"), a privately held, UK‑based innovator and manufacturer of medical devices and drug‑delivery technologies, in a transaction valued at up to £150 million. Under the terms of the agreement, embecta will acquire Owen Mumford for an upfront cash payment of £100 million at closing (subject to customary adjustments, including for closing net cash), and up to an additional £50 million in performance-based payments based on net sales of the A
- INSIDERDirector Anderson Carrie L was granted 22,841 shares, increasing direct ownership by 55% to 64,581 units (SEC Form 4)4 - Embecta Corp. (0001872789) (Issuer)
- INSIDERDirector Hombach Robert J. was granted 22,841 shares, increasing direct ownership by 55% to 64,587 units (SEC Form 4)4 - Embecta Corp. (0001872789) (Issuer)
- INSIDERDirector Morris Milton Mayo was granted 22,841 shares, increasing direct ownership by 61% to 60,121 units (SEC Form 4)4 - Embecta Corp. (0001872789) (Issuer)
- INSIDERDirector Prange Karen was granted 22,841 shares, increasing direct ownership by 55% to 64,581 units (SEC Form 4)4 - Embecta Corp. (0001872789) (Issuer)
- INSIDERDirector Pomeroy Claire was granted 22,841 shares, increasing direct ownership by 53% to 66,127 units (SEC Form 4)4 - Embecta Corp. (0001872789) (Issuer)
- INSIDERDirector Reidy Christopher R was granted 22,841 shares, increasing direct ownership by 48% to 70,122 units (SEC Form 4)4 - Embecta Corp. (0001872789) (Issuer)
- SECEmbecta Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Embecta Corp. (0001872789) (Filer)
EMBC FAQ
7 questionsWhat does Embecta Corp. do?
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.Where does EMBC stock trade?
Embecta Corp. (EMBC) is listed on NASDAQ.What sector and industry is EMBC in?
Embecta Corp. operates in the Health Care sector, Medical/Dental Instruments industry.Does EMBC pay a dividend?
EMBC's most recent ex-dividend date was 2026-05-28 with a cash dividend of $0.01 per share. No future ex-date is on file yet.What are analysts saying about EMBC?
Embecta Corp. has had 8 recent analyst actions on file. The most recent action was from BTIG Research: Neutral on 2026-05-06. Recent price targets range from $1500.00 to $3300.00.What companies are similar to EMBC?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare EMBC side-by-side with any of them on Quantisnow.How can I track EMBC on Quantisnow?
Quantisnow aggregates Embecta Corp.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow EMBC to receive live email and push alerts on every new disclosure.